Zipalertinib showed efficacy in NSCLC with EGFR exon 20 insertions, achieving a 31.3% intracranial ORR and a 27.6% systemic ORR. The drug demonstrated a favorable safety profile, with low rates of ...
As an editor and writer who has contributed to many national and local publications, Nicole Gregory enjoys communicating clearly on critical health topics so that readers can make informed choices for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback